GT
ITCI

Glenmede Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Glenmede Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,877
Closed -$658K – 1453
2024
Q4 		$658K Sell
7,877
-3,592
-31% -$295K ﹤0.01% 838
2024
Q3 		$839K Sell
11,469
-1,289
-10% -$96.9K ﹤0.01% 770
2024
Q2 		$874K Buy
+12,758
New +$885K ﹤0.01% 729
2020
Q4 		– Sell
-99
Closed -$2K – 2321
2020
Q3 		$2K Buy
99
+55
+125% +$1.25K ﹤0.01% 2299
2020
Q2 		$1K Buy
+44
New +$891 ﹤0.01% 2392
2017
Q3 		– Sell
-19,410
Closed -$315K – 2860
2017
Q2 		$315K Hold
19,410
– – ﹤0.01% 1063
2017
Q1 		$315K Hold
19,410
– – ﹤0.01% 1063
2016
Q4 		$292K Buy
19,410
+11,762
+154% +$166K ﹤0.01% 1103
2016
Q3 		$116K Buy
+7,648
New +$309K ﹤0.01% 1359

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Glenmede Trust's ITCI Position: Q1 2025 in Review

Glenmede Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 7,877 shares — an estimated $658K sold.

Glenmede Trust first reported a position in ITCI in Q3 2016 and held it in 9 quarters. The position peaked at $874K in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Glenmede Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Glenmede Trust sold 7,877 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $658K.
  • Glenmede Trust first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 9 quarters.
  • Glenmede Trust's Intra-Cellular Therapies Inc. position peaked at $874K in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.